Evidence map›Paper›PMID 33868935›Full record

ArticleUrology case reports2021

Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report.

Andrea Benedetto Galosi, Alessio Papaveri, Daniele Castellani, Edoardo Agostini, Luciano Burattini, Lucio Dell'Atti

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrea Benedetto GalosiDepartment of Specialist Clinical Science and Odontostomatology, Urology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Alessio PapaveriDepartment of Specialist Clinical Science and Odontostomatology, Urology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Daniele CastellaniDepartment of Specialist Clinical Science and Odontostomatology, Urology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Edoardo AgostiniDepartment of Specialist Clinical Science and Odontostomatology, Urology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Luciano BurattiniDepartment of Molecular and Clinical Science, Medical Oncology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Lucio Dell'AttiDepartment of Specialist Clinical Science and Odontostomatology, Urology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Up to 19% of patients with renal cell carcinoma present with a venous thrombus at diagnosis and 1% have a thrombus extending above the diaphragm. The higher the thrombus level, the more challenging the surgery. Cavoatrial tumor thrombus usually requires circulatory arrest and sometimes cardiopulmonary by-pass. We present a case of non-metastatic renal cell carcinoma with a cavoatrial tumor thrombus in a patient who was unfit for cardiac surgery. Eight months of targeted molecular therapy downsized the tumor thrombus to inferior vena cava and allowed us to perform a radical nephrectomy with minimal cavothomy for thrombus resection.

Indexed as

Cavoatrial tumor thrombusKidney neoplasmsPazopanibTargeted molecular therapies

Identifiers

PMID33868935
PMCPMC8044637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.